Art. 12 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2019cited 21×
1.

The marketing authorisation shall be refused if, after verification of the particulars and documents submitted in accordance with Article 6, it appears that the applicant has not properly or sufficiently demonstrated the quality, safety or efficacy of the medicinal product.

Authorisation shall likewise be refused if particulars or documents provided by the applicant in accordance with Article 6 are incorrect or if the labelling and package leaflet proposed by the applicant are not in accordance with Title V of Directive 2001/83/EC.

2.

The refusal of a Union marketing authorisation shall constitute a prohibition on the placing on the market of the medicinal product concerned throughout the Union.

3.

Information about all refusals and the reasons for them shall be made publicly accessible.

The 10 that are cited most themselves, of 21.

  • Judgment of the General Court (Second Chamber, Extended Composition) of 5 February 2018. Pari Pharma GmbH v European Medicines Agency.Decision

    Articles 11, 12, 36 and 37(3) of Regulation No 726/2004 also reflect the legislature’s intention that the MA procedure should be transparent, even where that procedure does not result in a decision or leads to a decision refusing MA. …

    5 Feb 2018 · 62015TJ0235

  • Ordonnance du président du Tribunal du 20 juillet 2016. PTC Therapeutics International Ltd contre Agence européenne des médicaments.Decision

    … is not possible to qualify as clearly incorrect the applicant’s argument that those regulations — in particular, Articles 11, 12(3), 13(3), 14(11), 24, 26, 57(1), point (1), 57(2), 76 and 80 of Regulation No 726/2004, Article 4(7) of …

    20 Jul 2016 · 62015TO0718(02)

  • Judgment of the General Court (Second Chamber) of 5 February 2018. PTC Therapeutics International Ltd v European Medicines Agency.Decision

    Articles 11, 12, 36 and 37(3) of Regulation No 726/2004 also reflect the legislature’s intention that the MA procedure should be transparent, even where that procedure does not result in a decision or leads to a decision refusing MA. …

    5 Feb 2018 · 62015TJ0718

  • Order of the Vice-President of the Court of 1 March 2017. European Medicines Agency (EMA) v PTC Therapeutics International Ltd.Decision

    In the first place, all documents submitted in connection with an MA application and, in particular, clinical and non-clinical studies, such as the report at issue, should enjoy a general presumption of confidentiality under Regulation No …

    1 Mar 2017 · 62016CO0513

  • Judgment of the General Court (Sixth Chamber) of 28 October 2020. Pharma Mar, SA v European Commission.Decision

    In support of the form of order sought in the application, the applicant raises five pleas in law, alleging, first, breach of the obligation requiring impartial examination of the application for marketing authorisation by the members of …

    28 Oct 2020 · 62018TJ0594

  • BGH, Urteil vom 6. Februar 2013 - I ZR 62/11Decision

    … § 37 Abs. 1 AMG in Verbindung mit Art. 12 Abs. 1 der Verordnung Nr. 726/2004/EG vom 31. März 2004 zur Festlegung von Gemeinschaftsverfahren für die Genehmigung und Überwachung von Human- und Tierarzneimitteln und zur Errichtung einer …

    6 Feb 2013 · KORE315382013

  • Order of the President of the Court of First Instance of 24 April 2009. Nycomed Danmark ApS v Agence européenne des médicaments (EMEA).Decision

    24 Apr 2009 · 62009TO0052

  • Judgment of the General Court (Second Chamber) of 5 February 2018. MSD Animal Health Innovation GmbH and Intervet international BV v EuropeaDecision

    Articles 11, 12, 36 and 37(3) of Regulation No 726/2004 also reflect the legislature’s intention that the MA procedure should be transparent, even where that procedure does not result in a decision or leads to a decision refusing MA. …

    5 Feb 2018 · 62015TJ0729

  • BSG, Urteil vom 13. Dezember 2016 - B 1 KR 10/16 RDecision

    13 Dec 2016 · KSRE144641517

  • Judgment of the General Court (Sixth Chamber) of 19 December 2019. Vanda Pharmaceuticals Ltd v European Commission.Decision

    The applicant submits, in essence, that, in requiring evidence of the ‘superiority’ of iloperidone over other second line medicinal products for schizophrenia, the contested decision infringes the principle of conferral, the principle …

    19 Dec 2019 · 62018TJ0211